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Burden of Neurological Disorders Across the US
From 1990-2017
A Global Burden of Disease Study
GBD 2017 US Neurological Disorders Collaborators
IMPORTANCE Accurate and up-to-date estimates on incidence, prevalence, mortality, and
disability-adjusted life-years (burden) of neurological disorders are the backbone of
evidence-based health care planning and resource allocation for these disorders. It appears
that no such estimates have been reported at the state level for the US.
OBJECTIVE To present burden estimates of major neurological disorders in the US states by
age and sex from 1990 to 2017.
DESIGN, SETTING, AND PARTICIPANTS This is a systematic analysis of the Global Burden of
Disease (GBD) 2017 study. Data on incidence, prevalence, mortality, and disability-adjusted
life-years (DALYs) of major neurological disorders were derived from the GBD 2017 study of
the 48 contiguous US states, Alaska, and Hawaii. Fourteen major neurological disorders were
analyzed: stroke, Alzheimer disease and other dementias, Parkinson disease, epilepsy,
multiple sclerosis, motor neuron disease, migraine, tension-type headache, traumatic brain
injury, spinal cord injuries, brain and other nervous system cancers, meningitis, encephalitis,
and tetanus.
EXPOSURES Any of the 14 listed neurological diseases.
MAIN OUTCOME AND MEASURE Absolute numbers in detail by age and sex and
age-standardized rates (with 95% uncertainty intervals) were calculated.
RESULTS The 3 most burdensome neurological disorders in the US in terms of absolute
number of DALYs were stroke (3.58 [95% uncertainty interval [UI], 3.25-3.92] million DALYs),
Alzheimer disease and other dementias (2.55 [95% UI, 2.43-2.68] million DALYs), and
migraine (2.40 [95% UI, 1.53-3.44] million DALYs). The burden of almost all neurological
disorders (in terms of absolute number of incident, prevalent, and fatal cases, as well as
DALYs) increased from 1990 to 2017, largely because of the aging of the population.
Exceptions for this trend included traumatic brain injury incidence (−29.1% [95% UI, −32.4%
to −25.8%]); spinal cord injury prevalence (−38.5% [95% UI, −43.1% to −34.0%]); meningitis
prevalence (−44.8% [95% UI, −47.3% to −42.3%]), deaths (−64.4% [95% UI, −67.7% to
−50.3%]), and DALYs (−66.9% [95% UI, −70.1% to −55.9%]); and encephalitis DALYs
(−25.8% [95% UI, −30.7% to −5.8%]). The different metrics of age-standardized rates varied
between the US states from a 1.2-fold difference for tension-type headache to 7.5-fold for
tetanus; southeastern states and Arkansas had a relatively higher burden for stroke, while
northern states had a relatively higher burden of multiple sclerosis and eastern states had
higher rates of Parkinson disease, idiopathic epilepsy, migraine and tension-type headache,
and meningitis, encephalitis, and tetanus.
CONCLUSIONS AND RELEVANCE There is a large and increasing burden of noncommunicable
neurological disorders in the US, with up to a 5-fold variation in the burden of and trends in
particular neurological disorders across the US states. The information reported in this article
can be used by health care professionals and policy makers at the national and state levels to
advance their health care planning and resource allocation to prevent and reduce the burden
of neurological disorders.
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A ccording to Gooch et al,1 in 2011, nearly 100 millionAmericans were affected by at least 1 of the more than1000 neurological disorders. This translates into an
overall cost of $765 billion for the more prevalent conditions,1
including Alzheimer disease (AD) and other dementias, chronic
low back pain, stroke, migraine, epilepsy, traumatic brain in-
jury (TBI), and Parkinson disease (PD). Although accurate data
on incidence, prevalence, mortality, and disability from neu-
rological disorders and their trends are important for evidence-
based health care planning and resource allocation, there is
a lack of national and state-level epidemiological data in the
US, as well as their synthesis for use by health care planners.
Previous Global Burden of Diseases, Injuries, and Risk
Factors (GBD) Study articles have reported burden of dis-
eases, injuries, and risk factors among US states2 and global,
regional, and country-specific estimates of the burden from
neurological disorders,3,4 but no estimates for a comprehen-
sive list of neurological disorders have been reported for the
US states from this study. Globally, regionally, and at the coun-
try level of analysis, the burden of all noncommunicable neu-
rological disorders, in terms of the absolute number of people
who had, remained disabled by, or died from them, has in-
creased significantly across all countries in the world, but the
burden from communicable neurological disorders, such as
tetanus, meningitis, and encephalitis, has decreased from 1990
to 2016.5-14 This study provides estimates for noncommuni-
cable and communicable neurological disorders at the state
level from 1990 to 2017.
Methods
Details on the methodology of the GBD study overall15 and in
association with the burden of neurological disorders have been
published elsewhere.5-14 In brief, using statistical modeling
techniques, the GBD study allows use of all available epi-
demiological data (both published and unpublished) and
routinely collected data (eg, vital registration, hospitaliza-
tions, medical claims) within and just outside of the country,
region, or state of interest to provide the most accurate esti-
mates of the disease burden, even for regions or states with
no accurate epidemiological data.15 The burden estimates are
presented in terms of age-adjusted annual rates per 100 000
people and numbers of prevalence, incidence, disability-
adjusted life-years (DALYs), and deaths by cause (in millions),
with corresponding 95% uncertainty intervals (UIs), and their
trends or changes from 1990 to 2017.
Nonfatal estimates were obtained from systematic re-
views, surveys, administrative health records, registries, and
disease surveillance systems. We used available surveys and
databases of claims information for US private and public in-
surance schemes, corrected for bias in health service encoun-
ters, as described elsewhere.2,16,17 Data sources used for quan-
tifying nonfatal outcomes are available online in the GBD
results tool.18 Fatal estimates were obtained from vital regis-
tration data (death records from the National Center for Health
Statistics and population counts from the US Census Bureau).
The single cause of death was determined using the Interna-
tional Classification of Diseases, Ninth Revision, Ninth Revi-
sion, Clinical Modification; International Statistical Classifi-
cation of Diseases and Related Health Problems, Tenth
Revision; and International Statistical Classification of Dis-
eases, Tenth Revision, Clinical Modification, with redistribu-
tions from less precise codes (such as ill-defined disease
[R99] or injuries of undetermined intent [Y21-Y33]) to more
specific diseases and injuries using regression methods of
the subset of vital registration data for which we have mul-
tiple causes of death information. Under International Clas-
sification of Diseases rules, injury deaths are classified by the
cause of injury (eg, fall or road injury) and not the nature of
injury, such as TBI and spinal cord injuries (SCI). Thus, we
report on incidence, prevalence, and years lived with dis-
ability for these causes, but not mortality. Causes of death
data were analyzed using the Cause of Death Ensemble
model (CODEm,19 with corrections for changes in coding
practices for underlying causes of death as explained in
detail elswhere20), and nonfatal data were analyzed using
DisMod-MR version 2.1 (World Health Organization),21 a
bayesian meta-regression tool that adjusts data points for
variations in study methods among different data sources
and enforces consistency between prevalence, incidence,
and mortality. For each disease and injury, years lived with
disability for mutually exclusive sequelae (ie, disabling out-
comes) were quantified as the product of prevalence and a
weighting for severity (with the GBD disability weights). Val-
ues for disability weights have been derived from popula-
tion surveys in 9 countries and an open-access internet
survey.22 To account for co-occurrence of disease and injury
outcomes, years lived with disability were corrected for
comorbidity, assuming a multiplicative rather than additive
function of disability weights.23,24
To allow comparison with the GBD estimates on the global
burden of neurological disorders,3 14 neurological disorders
that are quantified as part of GBD are included in this report.
Key Points
Question What is the current burden of neurological disorders in
the US by states, and what are the temporal trends (from 1990 to
2017)?
Findings Systematic analysis of the Global Burden of Disease
study shows that, in 2017, the 3 most burdensome neurological
disorders in the US were stroke, Alzheimer disease and other
dementias, and migraine. The burden of individual neurological
disorders varied moderately to widely by states (a 1.2-fold to
7.5-fold difference), and the absolute numbers of incident,
prevalent, and fatal cases and disability-adjusted life-years of
neurological disorders (except for traumatic brain injury incidence;
spinal cord injury prevalence; meningitis prevalence, deaths, and
disability-adjusted life-years; and encephalitis disability-adjusted
life-years) across all US states increased from 1990 to 2017.
Meaning A large and increasing number of people have various
neurological disorders in the US, with significant variation in the
burden of and trends in neurological disorders across the US
states, and the reasons for these geographic variations need to be
explored further.
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These are stroke, AD and other dementias, PD, idiopathic epi-
lepsy (ie, epilepsy that is not secondary to any of the other GBD
causes), multiple sclerosis (MS), motor neuron disease (MND),
migraine, tension-type headache (TTH), TBI, SCI, brain and
other central nervous system (CNS) cancers, meningitis, en-
cephalitis, and tetanus.
Results
Burden of Neurological Disorders in the US
Among the neurological disorders, the 5 most prevalent were
TTH (121.6 [95% UI, 110-133] million people), migraine (68.5
[95% UI, 64-73] million people), stroke (7.8 [95% UI, 7.4-8.2]
million people), AD and other dementias (2.9 [95% UI, 2.6-
3.2] million people), and SCI (2.2 [95% UI, 2.0-2.3] million
people) (Table 1), while the most burdensome in terms of DALYs
were stroke (3.6 [95% UI, 3.3-3.9] million DALYs), AD and other
dementias (2.6 [95% UI, 2.4-2.7] million DALYs), migraine (2.4
[95% UI, 1.5-3.4] million DALYs), idiopathic epilepsy (0.4 [95%
UI, 0.3-0.6] million people), and PD (0.4 [95% UI, 0.3-0.4] mil-
lion people). The 5 leading causes of death from neurological
disorders were from AD and other dementias (258 600 [95%
UI, 254 000-263 000] deaths), stroke (172 000 [95% UI,
166 000-178 000] deaths), PD (30 000 [95% UI, 24 000-
31 000] deaths), MND (8400 [95% UI, 8000-9000] deaths), and
MS (4000 [95% UI, 3000-4000] deaths). The highest inci-
dence was of new-onset TTH (44.5 [95% UI, 40.0-48.8] mil-
lion cases per year) followed by migraine (5.0 [95% UI, 4.6-
5.5] million cases per year), TBI (0.96 [95% UI, 0.8-1.2] million
cases per year), stroke (0.60 [95% UI, 0.55-0.65] million cases
per year), and AD and other dementias (0.48 [0.47-0.57] mil-
lion cases per year).
While the US-wide age-standardized incidence, preva-
lence, mortality, and DALY rates of most neurological disor-
ders declined or remained flat from 1990 through 2017
(Table 2), the absolute number of incident cases, prevalent
cases, mortality, and DALYs increased, except for meningitis
and encephalitis (Table 1). In 2017, the 5 highest incidence rates
were for TTH (13 014 [95% UI, 11 602-14 432] cases per 100 000
people), migraine (1722 [95% UI, 1578-1865] cases per 100 000
people), TBI (285 [95% UI, 238-341] cases per 100 000 people),
stroke (115 [95% UI, 107-125] cases per 100 000 people), and
AD and other dementias (85 [95% UI, 78-93] cases per 100 000
people). Prevalence was highest for TTH (34 642 [95% UI,
31 341-38 113] cases per 100 000 people), migraine (20 188 [95%
UI, 18 678-21 750] cases per 100 000 people), stroke (1536 [95%
UI, 1461-1621] cases per 100 000 people), SCI (541 [95% UI, 502-
583] cases per 100 000 people), and TBI (502 [95% UI, 478-
525] cases per 100 000 people). The 2 leading causes of mor-
tality were AD and other dementias (38 [95% UI, 38-39] per
100 000 population per year) and stroke (29 [95% UI, 28-30]
per 100 000 population per year). The 5 leading causes of
DALYs (rates) were migraine (705 [95% UI, 446-1021] per
100 000 population per year), stroke (692 [95% UI, 625-759]
per 100 000 population per year), AD and other dementias (419
[95% UI, 399-439] per 100 000 population per year), idio-
pathic epilepsy (124 [95% UI, 75-187] per 100 000 population
per year), and brain and other nervous system cancers (120
[95% UI, 111-138] per 100 000 population per year).
For stroke, from 1990 to 2017, there were significant re-
ductions in age-standardized incidence (−16.3% [95% UI,
−19.1% to −13.8%]), mortality (−32.0% [95% UI, −34.5% to
−29.8%]), and DALY (−24.0% [95% UI, −26.9% to −21.3]) rates,
but no significant change in age-standardized prevalence (0.2%
[95% UI, −3.8% to 3.3%]) (Table 2). Age-standardized DALY rates
of stroke stopped declining and plateaued around 2010, with
some nonsignificant trends to increase since 2015 (Figure 1;
eFigure in the Supplement). Age-standardized incidence and
prevalence of AD and other dementias decreased (−12.4% [95%
UI, −19.2% to −5.2%] and −13.4% [95% UI, −20.6% to −5.1%],
respectively), but mortality and DALY rates increased by 9.8%
(95% UI, 7.3%-12.2%) and 1.2% (95% UI, −1.9% to 4.2%), re-
spectively. For TBI and SCI, there were also significant de-
creases in age-standardized incidence (−29.1% [95% UI, −32.4%
to −25.8%] and −30.5% [95% UI, −34.8% to −26.2%], respec-
tively) and prevalence (−28.3% [95% UI, −29.7% to −26.9%] and
−38.5% [95% UI, −43.1% to −34.0%], respectively). Although
age-standardized mortality and DALY rates from brain and
other CNS cancers decreased (−3.4% [95% UI, −9.2% to 6.8%]
and −8.6% [95% UI, −15.5% to 5.4%], respectively), incidence
and prevalence rates increased significantly (24.1% [95% UI,
12.4%-41.4%] and 52.2% [95% UI, 36.7%-76.5%], respec-
tively). In meningitis, there were significant reductions in the
age-standardized rates of incidence (−28.7% [95% UI, −32.9%
to −24.4%]), prevalence (−44.8% [95% UI, −47.3% to −42.3%]),
mortality (−64.4% [95% UI, −67.7% to −50.3%]), and DALY
(−66.9% [95% UI, −70.1% to −55.9%]). In encephalitis, rates of
incidence (−0.1% [95% UI, −0.7% to 0.6%]), prevalence (−10.1%
[95% UI, −12% to −8.1%]), mortality (−20.6% [95% UI, −24.9%
to −1.7%]), and DALY (−25.8% [95% UI, −30.7% to −5.8%]) also
decreased. In PD, there were small but significant increases in
the age-standardized rates of incidence (21.9% [95% UI, 11.2%-
14.6%]), prevalence (16.2% [95% UI, 2.7%-31%]), mortality
(33.1% [95% UI, −4.6% to 41.7%]), and DALY (24.8% [95% UI,
−5.2% to 32.9%]) of PD. Age-standardized incidence (17.4%
[95% UI, −6% to 45.1%]), prevalence (15.2% [95% UI, −7.5% to
43.3%]), and DALY (5.5% [95% UI, −18.4% to 33.2%]) rates of
epilepsy increased, but mortality rates decreased (−2.7% [95%
UI, −7.8% to 1.5%]). There was an increase in the age-
standardized incidence, prevalence, mortality, and DALY rates
of MS (13.2% [95% UI, 7.3%-18.9%], 14.7% [95% UI, 8.1%-
21.3%], 32.8% [95% UI, −20.1% to 56.1%], and 16.6% [95%
UI, −1.4% to 26.2%], respectively) and MND (12.5% [95% UI,
9.8%-15.3%], 0.3% [95% UI, −4.4% to 5.6%], 38.3% [95%
UI, 30%-45.6%], and 20.9% [95% UI, 13.9%-27.6%], respec-
tively). There were small increases in the incidence, preva-
lence, and DALY age-standardized rates of migraine (1.6% [95%
UI, −0.8% to 4.2%], 1.4% [95% UI, −0.8% to 4%], and 1.5% [95%
UI, −0.8% to 4%], respectively) and TTH (0.4% [95% UI, −2.1%
to 2.9%], 0.5% [95% UI, −2% to 3.3%], and 0.1% [95% UI, −1.5%
to 1.9%], respectively).
However, the absolute numbers of people affected by non-
communicable neurological disorders (Table 1) in terms of in-
cident, prevalent, and fatal cases, as well as DALYs, have in-
creased substantially from 1990 to 2017 (except with respect
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to TBI incident and SCI prevalent cases, where small, nonsig-
nificant reductions were observed). The largest increases were
observed for (in order of increase) PD, MND, AD and other de-
mentias, brain and other CNS cancers, and stroke.
Burden of Selected Neurological Disorders in US States
Figure 2 and Figure 3 show age-standardized incidence, preva-
lence, mortality, and DALY rates of the selected neurological
disorders in the US states in 2017. Age-standardized preva-
lence, incidence, mortality, and DALY rates for specific neu-
rological disorders in the US states and changes in the rates from
1990 to 2017 and the US states’ ranking based on the 2017 es-
timates are described and shown in eTables 1 through 13 in the
Supplement.
The different metrics of age-standardized rates varied be-
tween the US states from a 1.2-fold difference for TTH to 7.5-
fold for tetanus. Southeastern states and Arkansas had a rela-
tively higher burden for stroke, northern states had a relatively
higher burden of MS, and eastern states had higher rates of PD,
idiopathic epilepsy, migraine, TTH, and meningitis, encepha-
litis, and tetanus (eFigure, eAppendix, and eTables 1 through
12 in the Supplement).
Changes in the Burden From 1990 to 2017
From 1990 to 2017, the direction of trends in changes in the
age-standardized incidence, prevalence, mortality, and DALY
rates across US states mirrored those for the country as a whole.
Over that period of time, there were very few changes in any
of the states in the rates of migraine and TTH.
Discussion
To our knowledge, this is the first comprehensive report on in-
cidence, prevalence, mortality, and DALY estimates and their
trends from 1990 to 2017 for 14 neurological disorders for
the individual 50 US states and the country overall. The study
showed reductions in the age-adjusted rates of most burden
metrics of stroke, AD and other dementias, TBI, SCI, menin-
gitis, and encephalitis, but increasing numbers of people af-
fected by various neurological disorders in the US, with a sig-
nificant (up to 5-fold) variation in the burden of and trends in
particular neurological disorders across the US states. Falling
rates of stroke, AD and other dementias, TBI, SCI, meningitis,
and encephalitis might suggest that primary prevention of
Figure 1. Temporal Trends in Aggregate US-Wide Age-Standardized Disability-Adjusted Life-Year (DALY) Rates
per 100 000 Persons per Year for Neurological Disorders From 1990 to 2017
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these disorders are beginning to show an influence, while be-
tween-state variations may be associated with differences in
the case ascertainment, as well as access to health care; racial/
ethnic, genetic, and socioeconomic diversity; quality and com-
prehensiveness of preventive strategies; and risk factor dis-
tribution. For dementia, improving educational levels of cohort
reaching the age groups at greatest risk of disease may also be
contributing to a modest decline over time.25 While globally,
6 neurological disorders (AD and other dementias, PD, epi-
lepsy, MS, MND, and headache disorders) in 2017 constituted
4.4% (95% UI, 3.7%-5.3%)26 of total DALYs and ranked ninth
among the leading causes of DALYs, in the US, they consti-
tuted 6.7% (95% UI, 6.0%-7.6%) and ranked fifth. In 2017,
deaths from these neurological disorders were ranked fifth
Figure 2. Disability-Adjusted Life-Year Rates per 100 000 Persons for Neurological Disorders in the US States in 2017
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(5.5% [95% UI, 5.4%-5.6%]) among all causes of death glob-
ally and third (10.8% [95% UI, 10.6%-10.9%]) in the US.26 Simi-
lar findings were observed for neurological disorders in West-
ern European countries.3 Given the association of prevalent
disorders, such as AD, stroke, PD, and MND with older age, the
higher rank of neurological disorders in the US can be ex-
plained by the longer life expectancy in the US compared with
the world overall. In addition, it may also be attributable to bet-
ter case ascertainment in the US, including improved diagno-
sis, surveillance or reporting, and health care access.
The exact causes for significant between-state variations
in the age-standardized rates of some neurological disorders
are unknown, but these may be associated with between-
state differences in the completeness of medical examina-
tions and accuracy of diagnosis, completeness and accuracy
of data from medical claims, and referral patterns to special-
ized centers (eg, seeking medical advice for brain tumors out-
side of the place of residence), despite corrections for these
measurement biases during data analysis. The highest be-
tween-state variations were observed for tetanus, but the num-
ber of tetanus cases was very low, and thus large relative varia-
tion reflected variation by just 1 or a few cases. However, our
data on between-state variations in the burden from neuro-
logical disorders concur with previous GBD observations of
large differences in the burden of disease among US states2 and
significant geographical variations in the burden of neurologi-
cal disorders in the world.3 For example, for stroke, there is a
strong increasing gradient from north to south, while for MS,
the gradient is decreasing from north to south. Both gradi-
ents might have been expected based on our understanding
of the epidemiology of both diseases.27-29 While confirming
previous observations of the so-called stroke belt mortality in
the southeastern United States, unlike previous estimates that
identified North Carolina, South Carolina, and Georgia with a
higher stroke mortality rate than the other states of the stroke
belt,30,31 our 2017 GBD stroke mortality estimates show that
the stroke belt is now in Alabama, Mississippi, and South
Carolina. Our dementia mortality estimates also showed a
higher percentage change (increase) in the stroke belt states
compared with the other states, likely attributable to the
Figure 3. Disability-Adjusted Life-Year Rates per 100 000 Persons for Neurological Disorders in the US States in 2017
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reciprocal association between stroke and dementia.32 These
findings can be used to set research priorities (eg, identifying
causes of between-state variations in the burden of neurologi-
cal disorders). These data will also allow health care pro-
fessionals and policy makers on national and state levels to
allocate resources (eg, number of hospital beds, specialists, ser-
vices) and give priorities for improving care for people with
some major neurological disorders in each US state.
The finding that the 3 most burdensome neurological dis-
orders in the US in terms of the absolute numbers of DALYs are
stroke, AD and other dementias, and migraine is in line with
ranking of age-standardized DALY rates for neurological dis-
orders found in other high-income countries in 2016.3 There
were diverse changes in the rates of all neurological disorders
in the country overall (eg, decreased incidence rates of stroke,
AD and other dementias, TBI, SCI, and meningitis, and in-
creased incidence rates of PD, MS, MND, and brain and other
nervous system cancers) and across all US states from 1990 to
2017. However, the absolute number of people who are af-
fected by noncommunicable neurological disorders over that
period has increased substantially and is likely to continue in-
creasing because of aging of the US population and popula-
tion growth. Unfavorable trends in some lifestyle factors (eg,
overweight, fasting plasma glucose level)2 in the US are also
likely additional contributing factors for the increasing bur-
den from some neurological disorders (eg, stroke, dementia).33
These developments are consistent with the global trends3 and
support the call to action to reduce the burden of neurologi-
cal disorders in the United States, as outlined by Gooch et al.1
Although we understand that individuals may have more
than 1 neurological condition, assuming no overlap between
stroke, TBI, SCI, brain and other CNS cancers, meningitis, en-
cephalitis, tetanus, and other neurological disorders (AD and
other dementias, PD, idiopathic epilepsy, MS, MND, mi-
graine, TTH, and other neurological disorders), it can be esti-
mated that in 2017 more than 200 million Americans (60% of
the population) were afflicted by at least 1 neurological disor-
der, ranging from TTH and migraine to stroke and dementia.
This is twice the estimate by Gooch et al1 and 9 times the
estimate by Borlongan et al.34 The greater than previously
reported overall prevalence of neurological disorders in the US
may be explained by at least 3 factors. First, we included many
disorders in this study that Gooch et al1 did not, such as TTH
(the most prevalent of all neurological disorders analyzed in
the GBD study), brain and other CNS cancers, tetanus, men-
ingitis, and encephalitis, although they1 did include chronic
low back pain, which we did not. The selection of neurologi-
cal disorders included in this analysis was largely based on 2
factors: (1) the GBD study currently provides estimates of
the burden of only these specific neurological disorders, and
(2) these neurological disorders are considered by the GBD
study as conditions for which neurologists play a particular im-
portant role in care and diagnosis (as opposed to, for ex-
ample, low back pain, for which the role of a neurologist is less
dominant). Second, Gooch et al1 based their analysis on pre-
viously published articles only, while the GBD study analyses
also included administrative data and modeling, thus allow-
ing estimates for US states with no epidemiological data on a
particular neurological disorder. Differences in the method-
ologies may explain differences in the estimates of stroke
prevalence (7.8 million in the GBD study vs 6.8 million in the
Gooch et al study1), AD and other dementias (2.9 million vs 5.3
million), epilepsy (1.4 million vs 2.8 million), TBI (2.1 million
vs 1.4 million), and SCI (2.2 million vs 0.3 million). The large
difference in SCI cases may reflect a weakness in GBD meth-
ods, which rely on sparse data on the association between the
incidence of a cause of injury (eg, falls and road injury) and
the nature of the injury (eg, fall or SCI), which should be ex-
amined in future rounds of GBD. Our GBD estimates of PD (0.6
million), migraine (69 million), MS (0.4 million), and MND
(38 000) are close to those reported by Gooch et al (0.6 mil-
lion, 72 million, 0.4 million, and 18 000-30 000, respectively).1
Third, the Gooch et al1 study was based on articles published
prior to 2017, with many of them referring to the data col-
lected 5 to 10 years ago; thus, ongoing aging of the population
and population growth may partly explain the greater preva-
lence of selected neurological disorders in our study.
Limitations
General limitations of the GBD study discussed elsewhere3
fully apply to this report and may account for differences
between these data and those collected by other governmen-
tal or disease-specific organizations. Specifically, for this
report, we were not able to provide burden estimates for all
neurological disorders combined, or burden estimates by age
and sex, because these estimates will be the subjects of sepa-
rate reports. In addition, some very prevalent neurological
disorders (eg, restless leg syndrome and peripheral neuropa-
thy are not currently estimated by GBD) and some common
disorders (eg, low back and neck pain) are not regarded as
neurological disorders in this article, although they are at
least partly within the realm of neurology. Inclusion of these
currently unaccounted disorders would increase the esti-
mates of the burden of neurological disorders. Other limita-
tions specific to this report include (1) difficulty in determin-
ing death from dementia because coding practices have
changed by orders of magnitude over the last 30 years; (2)
lack of data to quantify headaches in the US; and (3) accuracy
of medical claims and hospitalization data and potential inac-
curacies in the adjustments of administrative data to those
reported in epidemiological studies. Because GBD study esti-
mates are updated annually, the current limitations can be
addressed, and with an increasing amount of data being
added year to year, a more accurate picture of the burden of
neurological disorders in the US can be made.
Conclusions
In summary, this report showed that, while there were reduc-
tions in the rates of most burden metrics of stroke, Alzheimer
and other dementias, TBI, SCI, meningitis, and encephalitis,
there was a large and increasing number of people affected by
various neurological disorders in the US, with a significant
variation of the burden of and trends in particular neurologi-
cal disorders across the US states. The reasons for geographic
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variations among different US states need to be explored fur-
ther. Health care professionals and policy makers at the na-
tional and state levels can use the information reported in this
article to advance their health care planning and resource al-
location, including research funding, to prevent and reduce the
morbidity and mortality of neurological disorders.
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